Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Nov 4, 2015 (11 years ago)

Paricalcitol Capsules

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Tablet/Capsule Specifications: Product recalled due to reports of breakage and leakage of Paricalcitol capsules.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30

Affected NDC 55111-0665-30

Compare with the code on your package — it is the most precise check available.

Drug: Paricalcitol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Paricalcitol
NDC 55111-0665
4 ug/1 Capsule, Liquid Filled
Oral
Dr. Reddy's Laboratories Limited Rx
Recalling firm
Dr. Reddy's Laboratories, Inc.
NDC code
55111-665-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0721-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Paricalcitol recalls

See all
Class III · Low risk

Paricalcitol Capsules

Failed Impurities/Degradation Specifications: This repackaged product was recalled by its manufacturer due to failed results for impurities.

Terminated Impurity / degradation Amerisource Health Services NDC 60687-106-25 D-0009-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7658-56 D-0111-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7657-56 D-0110-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7656-56 D-0109-2017

Other recalls by Dr. Reddy's Laboratories, Inc.

All 2015 recalls
Class III · Low risk

Varenicline Tablets

Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.

Ongoing Wrong potency / content Dr. Reddy's Laboratories, Inc. NDC 43598-908-56 D-0219-2026
Class II · Moderate risk

Omeprazole Delayed-release Capsules

Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 82009-022-10 D-0525-2025
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025